四胺螯合剂优于HYNIC的新型锝-99m标记生长抑素受体2拮抗剂
本研究合成生长抑素受体2拮抗剂SS-01,分别偶联DOTA、N4和HYNIC并标记99mTc或177Lu,在HEK293-rsst2荷瘤小鼠中行生物分布与SPECT/CT。99mTc-N4-SS-01(99mTc-SS-04)注射后1小时肿瘤摄取达47%IA/g,24小时为32.5%IA/g,显像对比度高;而99mTc-HYNIC/edda-SS-01(99mTc-SS-05)体外几乎无细胞摄取。
要点
- 99mTc-SS-04在1小时肿瘤摄取47%IA/g,24小时为32.5%IA/g。
- 99mTc-SS-05体外几乎无细胞摄取,提示HYNIC螯合策略效果差。
- 99mTc-SS-04药代动力学和显像特性优良,作者认为适于SPECT/CT临床转化。
核心结论
- 数据表明99mTc标记的sst2靶向拮抗剂非常有前景。
- 99mTc标记策略灵敏度高,且与相应激动剂相反,强烈影响受体亲和力。
- 99mTc-SS-04药代动力学和显像特性优良,似乎是适合SPECT/CT临床转化的候选者。
研究设计与样本
- SS-01经Fmoc固相合成后分别偶联DOTA、N4和HYNIC,形成SS-03、SS-04和SS-05。
- SS-04和SS-05用99mTc标记,SS-03用177Lu标记。
- 用放射自显影和免疫荧光显微镜测定结合亲和力与拮抗特性。
- 在载HEK293-rsst2异种移植瘤的小鼠中行生物分布和小动物SPECT/CT研究。
主要发现
- 各偶联物显示低纳摩尔sst2亲和力和拮抗特性。
- 177Lu-DOTA-SS-01(177Lu-SS-03)和99mTc-N4-SS-01(99mTc-SS-04)显示高细胞结合和低内化。
- 99mTc-HYNIC/edda-SS-01(99mTc-SS-05)体外几乎无细胞摄取。
- 99mTc-SS-04注射后1小时肿瘤摄取为47%IA/g,4小时后持续,24小时为32.5%IA/g。
- 所有其他器官摄取下降更快,导致高肿瘤/正常器官比值,反映在高对比度SPECT/CT图像中。
关键数值与推荐
- 99mTc-SS-04注射后1小时肿瘤摄取47%IA/g。
- 99mTc-SS-04注射后24小时肿瘤摄取32.5%IA/g。
- 99mTc-SS-05体外几乎无细胞摄取。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Somatostatin receptor targeting radiopeptides are successfully being used to image, stage, and monitor patients with neuroendocrine tumours. They are exclusively agonists that internalise upon binding to the relevant receptor. According to recent reports, antagonists may be preferable to agonists. To date, 99mTc-labelled somatostatin receptor antagonists have attracted little attention. Here, we report on a new somatostatin receptor subtype 2 (sst2) antagonist, SS-01 (p-Cl-Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Thr-Cys)D-Tyr-NH2), with the aim of developing 99mTc-labelled ligands for SPECT/CT imaging. SS-01 was prepared using Fmoc solid-phase synthesis and subsequently coupled to the chelators 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 6-carboxy-1,4,8,11-tetraazaundecane (N4), and 6-hydrazinonicotinic acid (HYNIC) to form the corresponding peptide-chelator conjugates SS-03, SS-04, and SS-05, respectively. SS-04 and SS-05 were radiolabelled with 99mTc and SS-03 with 177Lu. Binding affinity and antagonistic properties were determined using autoradiography and immunofluorescence microscopy. Biodistribution and small animal SPECT/CT studies were performed on mice bearing HEK293-rsst2 xenografts. RESULTS: The conjugates showed low nanomolar sst2 affinity and antagonistic properties. 177Lu-DOTA-SS-01 (177Lu-SS-03) and 99mTc-N4-SS-01 (99mTc-SS-04) demonstrated high cell binding and low internalisation, whereas 99mTc-HYNIC/edda-SS-01 (99mTc-SS-05) showed practically no cellular uptake in vitro. The 99mTc-SS-04 demonstrated impressive tumour uptake at early time points, with 47% injected activity per gram tumour (%IA/g) at 1 h post-injection. The tumour uptake persisted after 4 h and was 32.5 %IA/g at 24 h. The uptake in all other organs decreased much more rapidly leading to high tumour-to-normal organ ratios, which was reflected in high-contrast SPECT/CT images. CONCLUSIONS: These data indicate a very promising 99mTc-labelled sst2-targeting antagonist. The results demonstrate high sensitivity of the 99mTc-labelling strategy, which was shown to strongly influence the receptor affinity, contrary to corresponding agonists. 99mTc-SS-04 exhibits excellent pharmacokinetics and imaging properties and appears to be a suitable candidate for SPECT/CT clinical translation.
引用
- Abiraj K, Ursillo S, Tamma ML, et al. The tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonist. EJNMMI Res. 2018. PMID: 30069789. doi:10.1186/s13550-018-0428-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。